Eumovate Cream GSK cream reduces symptoms of inflammation and itching of skin diseases (5g)

Out -inflammation;

Eumovate can be used to maintain alternatingly maintained between local steroid treatments.

Pharmacokology

corticosteroids used in place as an anti -inflammatory substance through many mechanisms to inhibit the late -phase allergic reaction, including reducing the density of mast cells, dynamic reduction and eucalyptus activity, reducing cytokin production from lymphocytes, mono cells, mast cells and eosinophilic cells, and inhibiting arachidonic acid metabolism.

Local corticosteroids have anti -inflammatory, anti -itching and vasoconstriction properties.

pharmacokinetics

absorption:

Local corticosteroids can absorb the whole body when exposed to normal healthy skin. Local corticosteroid absorption level depends on many factors such as the excipients of the drug and the intactness of the skin epidermis fence. Closed bandages, inflammation and/other diseases on the skin may also increase the absorption through the skin.

Distribution:

The use of pharmacological criteria to evaluate the body's systemic exposure is necessary because the circulating concentration is lower than the concentration that can detect the drug.

Metabolism:

Once the skin is absorbed, topical corticosteroids undergo a pharmacokinetic process like corticosteroids. The drug is metabolized mainly in the liver.

Era:

local corticosteroids are eliminated through the kidneys. In addition, some corticosteroids and their metabolites are eliminated through the bile.

Preceptic safety

Cancer properties:

Long -term studies on animals have not been conducted to evaluate the ability to produce cancer of Clobetasone used on the spot.

gene toxicity:

Clobetasone does not cause mutations on in vito and in vivo.

affect fertility:

The effect of clobetasone is used on the spot on the fertility that has not been evaluated in animals.

Pregnant animals:

Use Clobetasone on the spot for large mice in doses of 0.5 or 5 mg/kg/day, and use subcutaneously for mice with doses ≥ 3 mg/kg/day or rabbits in doses of ≥ 30 μgs/kg/day when these animals are pregnant causing abnormal embryos including open palate.

Skin and subcutaneous tissue disorders: allergic contact dermatitis, urticaria, skin atrophy, skin pigmentation changes, severely added hidden, burning symptoms in contact skin, hairy, rash, itching, red rash.

Instructions on how to handle ADR:

Notice to the doctor or pharmacist the harmful reactions encountered when using the drug.

Children and babies can absorb a large amount of corticosteroids than adults, so it is easy to experience unwanted effects. This is because children have immature skin barriers and surface area ratio compared to higher weight than adults.

Children: In children and children under 12 years old, if they can avoid prolonged treatment with local corticosteroids, because adrenal inhibition can be more likely to occur.

The risk of an infection of the skin is closed: warm, moist at the folds of the skin or when the skin is icy to facilitate the infection. Need to clean the skin before bandaging.

Use drugs on the face: Do not use the drug on the face because this area is prone to skin atrophy.

Use the drug on the eyelids: If applying the drug to the eyelids, it is necessary to be cautious to ensure that the drug does not enter the eyes because the contact many times can lead to cataracts and glaucoma.

Infections attached: appropriate antibiotic treatment when inflammatory lesions are treating local corticosteroids. When there are signs of widespread infection, local corticosteroids need to be stopped and appropriate antibiotics.

Chronic ulcer: Local corticosteroids are sometimes used to treat dermatitis around the chronic ulcer. However, this use may come with the occurrence of more hypersensitivity reactions and increase the risk of local infections.

Swallowing the wrong drug: The drug is only used on the skin. This preparation and all other drugs should be out of reach of children. In the case of swallowing drugs, immediately finding professional assistance or contacting the National Poisoning Center.

The ability to drive and operate machinery

There has been no investigation to investigate the effect of Eumovate 5 on driving or the ability to operate machinery. There is no adverse effect on these activities from the unwanted effects of Eumovate 5 used on the spot.

Pregnancy

data on the use of Eumovate 5 in pregnant women is limited.

Local corticosteroid use for pregnant animals can cause abnormalities for fetal development. The relationship of this finding with people has not been established. Consider the use of Eumovate 5 during pregnancy only when the expected benefits for the mother outstanding the risk of the fetus. Should use the least amount of drugs in the shortest treatment period.

The period of breastfeeding

has not established the safety of topical corticosteroids in the nursing women.

It is still unknown whether the use of local corticosteroids can cause enough body absorption to excrete an amount of drugs that can be detected in breast milk.

Should only consider using Eumovate 5 during breastfeeding when the expected benefits for the mother outperform the risk of children.

If you use the drug during breastfeeding, do not apply it to the breast to avoid swallowing the drug.

Drug interaction

Concomitant use with CYP3A4 inhibitors (e.g. Ritonavir, Itraconazole) showed that these drugs inhibit metabolism of corticosteroids leading to increased body contact. The degree of this interaction is clinically related, depending on the dose, the sugar uses corticosteroids and the effect of CYP3A4 inhibitors.